Ceapro Inc (CRPOF) 0.3094 $CRPOF
Ceapro Announces Appointment of New Chief Financial Officer
Marketwired - Tue May 05, 6:06AM CDT
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company"
, a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today it has appointed Stacy Prefontaine, CA, as Chief Financial Officer. Ms. Prefontaine replaces Branko Jankovic who is leaving his position effective immediately.
CZO.VN: 0.370 (-0.015)
Ceapro Appoints Seasoned Pharmaceutical Industry Executive, Ulrich Kosciessa, Ph.D., to its Board of Directors
Marketwired - Tue Apr 28, 7:03AM CDT
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company", a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today it has appointed international pharmaceutical industry expert, Ulrich Kosciessa, Ph.D., to its Board of Directors.
CZO.VN: 0.370 (-0.015)
Ceapro Reports Record Full-Year 2014 Financial Results
Marketwired - Wed Apr 22, 7:02AM CDT
Ceapro Inc. (TSX VENTURE: CZO) (Ceapro or the Company), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today its financial results for the twelve-months ended December 31, 2014 and provided an overview of recent operational highlights and expected business milestones for 2015.
CZO.VN: 0.370 (-0.015)
Ceapro Expands License Agreement With University of Alberta for PGX Technology
Marketwired - Wed Feb 11, 7:03AM CST
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company", a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced an expansion to its agreement with the University of Alberta for the development and commercialization of an innovative drying technology called Pressurized Gas eXpanded Technology (PGX) to include all fields of use, including emerging industrial opportunities. The original agreement was established in April 2014 for the development and commercialization of the PGX technology in select large markets like cosmeceuticals, functional food, nutraceuticals and pharmaceuticals.
CZO.VN: 0.370 (-0.015)
Ceapro Raises an Additional $310,000 Through a Non-Brokered Private Placement
Marketwired - Wed Feb 04, 4:01PM CST
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company", a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that it has closed a $310,000 second tranche of its previously announced private placement of eight (
percent unsecured convertible debentures (the "Debentures" due December 31, 2016, with interest payable on June 30 and December 31 of each year.
CZO.VN: 0.370 (-0.015)
Ceapro Raises $650,000 through a Non-Brokered Private Placement
Marketwired - Wed Jan 21, 5:00PM CST
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company", a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that it has received conditional TSX-V approval for and has closed a $650,000 first tranche private placement of eight ( percent unsecured convertible debentures (the "Debentures" due December 31, 2016, with interest payable on June 30 and December 31 of each year.
CZO.VN: 0.370 (-0.015)
Ceapro to Present at the Eighth Annual OneMedForum on Tuesday, January 13, 2015
Marketwired - Thu Jan 08, 7:05AM CST
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company", a growth-stage biotechnology company focused on the development and commercialization of active ingredients for health care and cosmetic industries, announced today that its President and Chief Executive Officer, Gilles Gagnon M.Sc., MBA, will be presenting at the Eighth Annual OneMedForum being held January 12 - 13, 2015, at the Marriott Marquis in San Francisco, CA.
CZO.VN: 0.370 (-0.015)
Ceapro Announces Grant of Stock Options
Marketwired - Wed Jan 07, 6:01PM CST
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company", today announced the granting of stock options to its employees, directors, and officers for a total of 950,000 stock options, each with an exercise price of $0.64. Each grant vests in three equal instalments, the first of which vests immediately with the second and third instalments vesting on the first and second anniversaries of the date of grant. Each option is exercisable, once vested, for a period of ten years from the date of grant.
CZO.VN: 0.370 (-0.015)
Ceapro Enters into Financing Agreement with Agriculture Financial Services Corporation
Marketwired - Thu Dec 18, 7:36AM CST
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company", a growth-stage biotechnology company focused on the development and commercialization of active ingredients for health care and cosmetic industries, announced today that it has signed an Offer Letter with Agriculture Financial Services Corporation (AFSC) for a commercial financing of up to $900,000.
CZO.VN: 0.370 (-0.015)
Ceapro Awarded Research Grant from Alberta Innovates Bio Solutions to Develop Novel Formulations for Energy Drink
Marketwired - Thu Dec 04, 7:06AM CST
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company", a growth-stage biotechnology company focused on the development and commercialization of active ingredients for health care and cosmetic industries, announced today that it has been awarded a non-reimbursable grant of $198,000 by Alberta Innovates Bio Solutions (AI Bio) to develop the Company's proprietary Beta Glucan formulation in combination with certain bioactives, for use in an energy drink. The AI Bio grant will support a collaborative research project being conducted with Professor Feral Temelli, Ph.D., at the Department of Agricultural, Food & Nutritional Science at the University of Alberta.
CZO.VN: 0.370 (-0.015)
Ceapro Announces Appointment of New Chief Financial Officer
Marketwired - Tue May 05, 6:06AM CDT
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company"
, a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today it has appointed Stacy Prefontaine, CA, as Chief Financial Officer. Ms. Prefontaine replaces Branko Jankovic who is leaving his position effective immediately. CZO.VN: 0.370 (-0.015)
Ceapro Appoints Seasoned Pharmaceutical Industry Executive, Ulrich Kosciessa, Ph.D., to its Board of Directors
Marketwired - Tue Apr 28, 7:03AM CDT
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company"
, a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today it has appointed international pharmaceutical industry expert, Ulrich Kosciessa, Ph.D., to its Board of Directors. CZO.VN: 0.370 (-0.015)
Ceapro Reports Record Full-Year 2014 Financial Results
Marketwired - Wed Apr 22, 7:02AM CDT
Ceapro Inc. (TSX VENTURE: CZO) (Ceapro or the Company), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today its financial results for the twelve-months ended December 31, 2014 and provided an overview of recent operational highlights and expected business milestones for 2015.
CZO.VN: 0.370 (-0.015)
Ceapro Expands License Agreement With University of Alberta for PGX Technology
Marketwired - Wed Feb 11, 7:03AM CST
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company"
, a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced an expansion to its agreement with the University of Alberta for the development and commercialization of an innovative drying technology called Pressurized Gas eXpanded Technology (PGX) to include all fields of use, including emerging industrial opportunities. The original agreement was established in April 2014 for the development and commercialization of the PGX technology in select large markets like cosmeceuticals, functional food, nutraceuticals and pharmaceuticals. CZO.VN: 0.370 (-0.015)
Ceapro Raises an Additional $310,000 Through a Non-Brokered Private Placement
Marketwired - Wed Feb 04, 4:01PM CST
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company"
, a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that it has closed a $310,000 second tranche of its previously announced private placement of eight ( percent unsecured convertible debentures (the "Debentures" due December 31, 2016, with interest payable on June 30 and December 31 of each year. CZO.VN: 0.370 (-0.015)
Ceapro Raises $650,000 through a Non-Brokered Private Placement
Marketwired - Wed Jan 21, 5:00PM CST
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company"
, a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that it has received conditional TSX-V approval for and has closed a $650,000 first tranche private placement of eight ( percent unsecured convertible debentures (the "Debentures" due December 31, 2016, with interest payable on June 30 and December 31 of each year. CZO.VN: 0.370 (-0.015)
Ceapro to Present at the Eighth Annual OneMedForum on Tuesday, January 13, 2015
Marketwired - Thu Jan 08, 7:05AM CST
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company"
, a growth-stage biotechnology company focused on the development and commercialization of active ingredients for health care and cosmetic industries, announced today that its President and Chief Executive Officer, Gilles Gagnon M.Sc., MBA, will be presenting at the Eighth Annual OneMedForum being held January 12 - 13, 2015, at the Marriott Marquis in San Francisco, CA. CZO.VN: 0.370 (-0.015)
Ceapro Announces Grant of Stock Options
Marketwired - Wed Jan 07, 6:01PM CST
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company"
, today announced the granting of stock options to its employees, directors, and officers for a total of 950,000 stock options, each with an exercise price of $0.64. Each grant vests in three equal instalments, the first of which vests immediately with the second and third instalments vesting on the first and second anniversaries of the date of grant. Each option is exercisable, once vested, for a period of ten years from the date of grant. CZO.VN: 0.370 (-0.015)
Ceapro Enters into Financing Agreement with Agriculture Financial Services Corporation
Marketwired - Thu Dec 18, 7:36AM CST
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company"
, a growth-stage biotechnology company focused on the development and commercialization of active ingredients for health care and cosmetic industries, announced today that it has signed an Offer Letter with Agriculture Financial Services Corporation (AFSC) for a commercial financing of up to $900,000. CZO.VN: 0.370 (-0.015)
Ceapro Awarded Research Grant from Alberta Innovates Bio Solutions to Develop Novel Formulations for Energy Drink
Marketwired - Thu Dec 04, 7:06AM CST
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company"
, a growth-stage biotechnology company focused on the development and commercialization of active ingredients for health care and cosmetic industries, announced today that it has been awarded a non-reimbursable grant of $198,000 by Alberta Innovates Bio Solutions (AI Bio) to develop the Company's proprietary Beta Glucan formulation in combination with certain bioactives, for use in an energy drink. The AI Bio grant will support a collaborative research project being conducted with Professor Feral Temelli, Ph.D., at the Department of Agricultural, Food & Nutritional Science at the University of Alberta. CZO.VN: 0.370 (-0.015)
